Enterprise Value
3.984B
Cash
890.9M
Avg Qtr Burn
-14.54M
Short % of Float
10.50%
Insider Ownership
2.37%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Emflaza (deflazacort) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
Evrysdi (riskiplam) Details Spinal muscular atrophy | Approved Quarterly sales | |
Upstaza (PTC-AADC) Details Aromatic L-amino acid decarboxylase deficiency | PDUFA Approval decision | |
Translarna (ataluren) Details Duchenne muscular dystrophy | NDA Resubmission | |
Vatiquinone (PTC743) Details Friedreich’s Ataxia | NDA Submission | |
Sepiapterin (PTC923) Details Phenylketonuria | NDA Submission | |
PTC518 Details Huntington's disease | Phase 2 Data readout | |
Utreloxastat Details Amyotrophic lateral sclerosis | Phase 2 Data readout | |
Vatiquinone (PTC743) Details Epilepsy, Mitochondrial disease | Failed Discontinued | |
PTC299 (DHODH inhibitor) Details COVID-19 | Failed Discontinued |